Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study

BACKGROUND: Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. No pharmacotherapy has been shown to be beneficial. METHODS: In this single...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Kelly, Brendan, Vidal, Louise, McHugh, Tina, Woo, James, Avramovic, Gordana, Lambert, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250701/
https://www.ncbi.nlm.nih.gov/pubmed/35814187
http://dx.doi.org/10.1016/j.bbih.2022.100485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250701/
https://www.ncbi.nlm.nih.gov/pubmed/35814187
http://dx.doi.org/10.1016/j.bbih.2022.100485

Ejemplares similares